

Listing of the Claims

1. A composition for the treatment of psoriasis produced by the step comprising mixing together effective amounts of 3-methylantralin, chrysophanol, aloe-emodin and aloe-emodin monoacetate.
2. The composition recited in claim 1, further comprising a derivative of at least one of the compounds 3-methylantralin, chrysophanol, aloe-emodin, and aloe-emodin monoacetate.
3. A method for treating psoriasis comprising the steps of:
mixing together 3-methylantralin, chrysophanol, aloe-emodin, and aloe-emodin monoacetate;
and
applying the mixture to an area of skin affected by psoriasis with sufficient frequency to effect an alleviation of psoriatic symptoms.
4. The method recited in claim 3, wherein the mixing step further comprises the step of adding to the mixture a derivative of at least one of the compounds 3-methylantralin, chrysophanol, aloe-emodin, and aloe-emodin monoacetate.
5. A method for making an antipsoriatic composition comprising the step of mixing together 3-methylantralin, chrysophanol, aloe-emodin, and aloe-emodin monoacetate.
6. The method recited in claim 5, further comprising the step of adding to the mixture a derivative of at least one of the compounds 3-methylantralin, chrysophanol, aloe-emodin, and aloe-emodin monoacetate.
7. A composition comprising an extract from *Asphodelus microcarpus* and a pharmaceutical carrier for topical administration.
8. The composition of Claim 7, wherein said pharmaceutical carrier is selected from the group consisting of gels, sprays, creams, and dermal patches.

9. The composition of Claim 7, wherein said pharmaceutical carrier is a cream.
10. The composition of Claim 7, wherein said pharmaceutical carrier is a gel.
11. The composition of Claim 7, wherein said extract is included in said pharmaceutical carrier in an amount effective to reduce the symptoms of psoriasis.
12. The composition of Claim 7, wherein said extract comprises effective amounts of 3-methylantralin, chrysophanol, aloe-emodin, and aloe-emodin acetate.
13. A method for treating psoriasis comprising
a) providing:
i) a composition comprising an extract from *Asphodelus microcarpus* and a pharmaceutical carrier for topical administration; and
ii) a patient having symptoms psoriasis; and
b) topically applying said composition to said patient under conditions such that said symptoms of psoriasis are reduced.
14. The method of Claim 13, wherein said pharmaceutical carrier is selected from the group consisting of liquids, gels, sprays, creams, and dermal patches.
15. The method of Claim 13, wherein said pharmaceutical carrier is a cream.
16. The method of Claim 13, wherein said pharmaceutical carrier is a gel.
17. The method of Claim 13, wherein said extract is included in said pharmaceutical carrier in an amount effective to reduce the symptoms of psoriasis.
18. The method of Claim 13, wherein said extract comprises effective amounts of 3-methylantralin, chrysophanol, aloe-emodin, and aloe-emodin acetate.

19. A method for prepraing a pharmeceutical preparation comprising:
- a) providing:
 - i) an extract from *Asphodelus microcarpus*; and
 - ii) a pharmaceutical carrier for topical administration; and
 - b) preparing a pharmaceutical preparation from said extract and said pharmaceutical carrier.
20. The method of Claim 19, wherein said pharmaceutical carrier is selected from the group consisting of liquids, gels, sprays, creams, and dermal patches.
21. The method of Claim 19, wherein said pharmaceutical carrier is a cream.
22. The method of Claim 19, wherein said pharmaceutical carrier is a gel.
23. The method of Claim 19, wherein said extract is included in said pharmaceutical carrier in an amount effective to reduce the symptoms of psoriasis.
24. The method of Claim 19, wherein said extract comprises effective amounts of 3-methylantralin, chrysophanol, aloe-emodin, and aloe-emodin acetate.
25. A pharmaceutical preparation prepared according to Claim 19.
26. A composition comprising an effective amount of purified aloe-emodin monoacetate in a pharmaceutical carrier.
27. The composition of Claim 26, wherein said effective amount is an amount sufficient to relieve the symptoms of psoriasis in a patient.
28. The composition of Claim 26, further comprising at least one compound selected from the group consisting of 3-methylantralin, chrysophanol, and aloe-emodin.

29. The composition of Claim 26, wherein said composition further comprises 3-methylantralin and chrysophanol.

30. The composition of Claim 26, wherein said pharmaceutical carrier is selected from the group consisting of pills, tablets, capsules, liquids, gels, sprays, creams, dermal patches, and suppositories.

31. The composition of Claim 26, wherein said pharmaceutical carrier is a cream.

32. The composition of Claim 26, wherein said pharmaceutical carrier is a gel.

33. A composition comprising a cream including an effective amount of aloe-emodin monoacetate.

34. A composition comprising a gel including an effective amount of aloe-emodin monoacetate.

35. A method for preparing a pharmaceutical preparation comprising:

- a) providing purified aloe-emodin monoacetate; and
- b) formulating said pharmaceutical preparation, wherein said pharmaceutical preparation comprises an effective amount of said substantially purified aloe-emodin monoacetate.

36. The method of Claim 35, wherein said effective amount is an amount sufficient to relieve the symptoms of psoriasis in a patient.

37. The method of Claim 35, further comprising providing at least one compound selected from the group consisting of 3-methylantralin, chrysophanol, and aloe-emodin and combining said at least one compound with said aloe-emodin monoacetate to provide said preparation.

38. The method of Claim 35, wherein said pharmaceutical carrier is selected from the group consisting of pills, tablets, capsules, liquids, gels, sprays, creams, dermal patches, and suppositories.

39. The method of Claim 35, wherein said pharmaceutical carrier is a cream.

40. The method of Claim 35, wherein said pharmaceutical carrier is a gel.

41. A method for preparing a pharmaceutical preparation comprising:

a) providing purified aloe-emodin monoacetate and at least one compound selected from the group consisting of 3-methylanthralin, chrysophanol, and aloe-emodin; and

b) formulating said pharmaceutical preparation, wherein said pharmaceutical preparation comprises an effective amount of said purified aloe-emodin monoacetate and said at least one compound selected from the group consisting of 3-methylanthralin, chrysophanol, and aloe-emodin.

42. The method of Claim 41, wherein said effective amount is an amount sufficient to relieve the symptoms of psoriasis in a patient.

43. The method of Claim 41, wherein said pharmaceutical preparation is selected from the group consisting of pills, tablets, capsules, liquids, gels, sprays, creams, dermal patches, and suppositories.

44. A method for preparing a pharmaceutical gel or cream comprising:

a) providing purified aloe-emodin monoacetate; and

b) preparing a pharmaceutical gel or cream comprising an effective amount of said aloe-emodin monoacetate.

45. The method of Claim 44, further comprising providing at least one compound selected from the group consisting of 3-methylanthralin, chrysophanol, and aloe-emodin and combining said at least one compound with said aloe-emodin monoacetate to provide said preparation.

46. A method for inhibiting keratinocyte proliferation comprising

a) providing

i) keratinocytes and

ii) a composition comprising an effective amount of aloe-emodin monoacetate; and

b) applying said composition to said keratinocytes, wherein said effective amount is sufficient to inhibit keratinocyte proliferation as compared to control samples.

merge a and b

47. The method of Claim 46, wherein composition further comprises at least one compound selected from the group consisting of 3-methylanthralin, chrysophanol, and aloe-emodin.

48. The method of Claim 46, wherein said composition is a cream.

49. The method of Claim 46, wherein said composition is a gel.


50. The method of Claim 46, wherein said keratinocytes are from a patient suffering from psoriasis.

51. The method of Claim 46, wherein said keratinocytes are from a patient suffering from eczema.

Conclusion

Applicants believe this response is responsive to the Office Action dated 10/02/01. If the Examiner has any questions, she is encouraged to contact the undersigned at 608-218-6900.

Dated: September 24, 2003



J. Mitchell Jones
Registration No. 44,174

MEDLEN & CARROLL, LLP
101 Howard Street, Suite 350
San Francisco, California 94105
415.904.6500

RECEIVED
OCT 01 2003
OFFICE OF PETITIONS